USPTO grants ReST Therapeutic’s Patent on PTSD

On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of its drug candidate FENM for the treatment of anxiety and PTSD. ReST Therapeutics’  project is to develop a proprietary drug candidate for the treatment of  Post-Traumatic Syndrome and...